A story in the Nov. 16, 2000, issue of BioWorld Today said Avigen Inc.'s cash and cash equivalents were $1.19 million as of Sept. 30. That did not take into account $72.2 million the company had in marketable securities, giving it about $160 million on hand after recent financings.

Editor's Note: The correction will be made Friday in BioWorld Online.